BROOKLYN PARK, Minnesota– CHF Solutions Inc. raised $1.8 million from investors, according to documents filed with the Securities and Exchange Commission.
The company is seeking a total of $2.3 million from the sale of equity.
Founded in 1999, CHF’s core technology is the Aquadex FlexFlow System, a device that removes excess fluids, primarily water, from the blood of patients suffering from congestive heart failure, renal failure, metabolic diseases and post-surgery complications.
Integrating GLP-1s: How Berry Street is Redefining Nutrition Care
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
CHF president and CEO David Springer did not immediate return a call for comment.